FHTX
Foghorn
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
FHTX Profile
Foghorn Therapeutics Inc.
A developer of therapeutics for genetically determined dependencies within the chromatin regulatory system
Biological Technology
Invalid Date
10/23/2020
NASDAQ Stock Exchange
112
12-31
Common stock
500 Technology Square, Ste 700, Cambridge, Massachusetts 02139
--
Foghorn Therapeutics Inc., was founded in October 2015. The company pioneered the discovery and development of a class of drugs targeting genetic deterministic dependence within the chromatin regulatory system, an untapped therapeutic opportunity intervention. The company's proprietary gene flow control platform provides it with a comprehensive, mechanical understanding of how the various components of the chromatin regulatory system interact, enabling it to identify and validate potential drug targets within the system.